Print

Featured Studies Results

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/353 /using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer

Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)

Prevention
Screening for people at high risk for prostate cancer

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/360 /the-prostate-cancer-genetic-risk-and-equitable-screening-study-progress

Clinicaltrials.gov identifier:
NCT05926102 (https://clinicaltrials.gov/show/NCT05926102)

Prevention
Prostate cancer screening study for male US veterans age 55–69

Understanding Access to Genetic Services for Latina Women with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/367 /understanding-access-to-genetic-services-for-latina-women-with-breast-cancer

Surveys, Registries, Interviews
A phone survey for Latina breast cancer survivors diagnosed within the past five years in California

Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors

Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)

https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer

Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)

Treatment
Treatment study for people with advanced solid tumors

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2

Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)

Treatment
Phase 1 treatment study for metastatic solid tumors

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for MMR-D or MSI-H Stage IIB - III Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/358 /post-surgery-immunotherapy-toripalimab-for-mmr-d-msi-h-stage-iib-iii-colon-cancer

Clinicaltrials.gov identifier:
NCT07140679 (https://clinicaltrials.gov/show/NCT07140679)

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD

https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd

Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)

https://www.facingourrisk.org/research-clinical-trials/study/347 /testing-higher-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT06958328 (https://clinicaltrials.gov/show/NCT06958328)

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)

https://www.facingourrisk.org/research-clinical-trials/study/369 /a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer

Clinicaltrials.gov identifier:
NCT06952803 (https://clinicaltrials.gov/show/NCT06952803)

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Pancreatic Cancer Screening Study for People with ATM, BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/330 /screening-study-for-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT05058846 (https://clinicaltrials.gov/show/NCT05058846)

Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations

PREVAIL Study: A Genetic Education and Genetic Testing Study for African American Men with Prostate Cancer or with a Strong Family History of Cancer

https://www.facingourrisk.org/research-clinical-trials/study/351 /prevail-study-a-genetic-education-and-genetic-testing-study-for-african-american-men-with-prostate-cancer-or-with-a-strong-family-history-of-cancer

Surveys, Registries, Interviews
Study for African American men with prostate cancer or with a strong family history of cancer

Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact

https://www.facingourrisk.org/research-clinical-trials/study/357 /understanding-the-cancer-journey-a-survey-of-patient-experiences-and-emotional-impact

Surveys, Registries, Interviews
Survey for people diagnosed with lung, liver, pancreatic or thyroid cancer

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01

Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression

https://www.facingourrisk.org/research-clinical-trials/study/352 /an-online-program-to-help-asian-american-breast-cancer-survivors-manage-pain-and-depression

Clinicaltrials.gov identifier:
NCT06085313 (https://clinicaltrials.gov/show/NCT06085313)

Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs

Clinicaltrials.gov identifier:
NCT06167317 (https://clinicaltrials.gov/show/NCT06167317)

Treatment
Treatment study for people with advanced or metastatic solid tumors

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.